Accustem Sciences Inc's Comment on Sales, Marketing and Customers
The company focuses on the breast cancer market, specifically targeting endocrine receptor positive (ER+) breast cancer patients, who represent approximately 75% of breast cancer cases. Their product, StemPrintER, is intended for early-stage breast cancer patients, particularly those who are ER+/HER2-. The assay is designed to assess a patient's risk of recurrence to support treatment planning. The estimated U.S. patient population for this market is 214,000, with a serviceable market opportunity exceeding $800 million annually. StemPrintER was developed and validated using patient data from the IEO and the TransATAC trial, emphasizing the biological role of cancer stem cells in predicting patient outcomes.
Accustem Sciences Inc’s Comment on Sales, Marketing and Customers
The company focuses on the breast cancer market, specifically targeting endocrine receptor positive (ER+) breast cancer patients, who represent approximately 75% of breast cancer cases. Their product, StemPrintER, is intended for early-stage breast cancer patients, particularly those who are ER+/HER2-. The assay is designed to assess a patient's risk of recurrence to support treatment planning. The estimated U.S. patient population for this market is 214,000, with a serviceable market opportunity exceeding $800 million annually. StemPrintER was developed and validated using patient data from the IEO and the TransATAC trial, emphasizing the biological role of cancer stem cells in predicting patient outcomes.
Sources:
Accustem Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Accustem Sciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Accustem Sciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
